China's CanSino in talks for COVID vaccine Phase III trial overseas - (Fidelity via NewsPoints Desk)

  • CanSino Biologics co-founder Qiu Dongxu said the company is in talks with Russia, Brazil, Chile and Saudi Arabia to launch a Phase III trial of its experimental COVID-19 vaccine, as reported Fidelity on Saturday.

  • He said the study was likely to start "pretty soon," and the company plans to recruit 40,000 participants.

  • CanSino Biologics' COVID-19 candidate, Ad5-nCov, became the first in China to move into clinical trials in March but is running behind other potential vaccines in terms of trial progress.

  • Two experimental vaccines developed by Sinovac Biotech and a unit of China National Pharmaceutical Group (Sinopharm) are already approved for Phase III trials.

  • Qiu said its Phase II trial involving 508 people yielded "much better" results than the Phase I study, adding that the company's new factory under construction in China will allow it to produce 100 to 200 million doses of COVID-19 vaccines per year by early 2021.

To read more NewsPoints articles, click here.